Navigation Links
AMT Announces Management Changes in Light of Refocused Strategy
Date:12/2/2009

AMSTERDAM, December 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a number of management changes. Piers Morgan (age 43) has been appointed Chief Financial Officer, effective December 1, 2009. Hans Preusting, PhD (age 47), Director Process Development & Manufacturing, will take up the responsibility for Operations and Project Management, also effective December 1. These changes reflect the refocused strategy of the company announced in the third quarter update on 18 November 2009.

In addition to the anticipated filing for regulatory approval of its lead product Glybera(R), a gene therapy product to control LipoProtein Lipase Deficiency (LPLD), AMT is focusing on accelerating the development of 4 of its pipeline products, using its stable and scalable AAV (adeno-associated viral vector) production platform. These projects are Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria and Parkinson's Disease. Furthermore AMT is implementing a business model combining proprietary and partnered development of these products in order to retain value and conserve cash.

Piers Morgan is a University of Cambridge graduate (MA in Law and Management Studies), who received his ACA Qualification while at PriceWaterhouseCoopers, and who worked in M&A advisory with Close Brothers Corporate Finance and Ernst & Young before starting his career in biotechnology. He was Finance Director for Arrow Therapeutics where he successfully raised equity and debt capital, became CFO of BioAlliance Pharma SA in Paris, France, where he led the company's IPO on Euronext, and recently was CFO and CBO at Phytopharm plc in the UK. He will succeed Andre Verwei, who was as AMT's CFO as from 2005.

Before joining AMT in 2006, Hans Preusting had more than 14 years of experience in the production process of biologic
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
(Date:7/24/2014)... Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased by ... Reported sales increased 5% which included a 1% benefit ... as reported (EPS) were $2.49, compared with $2.24 in ... an increase of 9% over the prior-year amount of ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 DON’T PAUSE ... help alleviate uncomfortable bloating, hot flashes, mood swings, burning ... identified by Dr. Shoreh Ershadi. The AntiAging Institute of California ... Menopause that allows women to try this revolutionary product. For ... PAUSE can get a third bottle at no charge. ...
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... Researchers at the University of Bordeaux in Bordeaux, France have ... man-made material used in high-heat insulation may increase the risk ... has just posted an article on the new study. ... French scientists studied the work histories of 988 men ... group of workers had been exposed to asbestos only while ...
(Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... for the Guinness International Champions Cup Match between Manchester ... Bronx, New York, one of the most iconic locations is ... original Yankee Stadium, but it is quickly becoming a location ... The facility is home to the New York Yankees from ...
(Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 2Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2
... , NASHVILLE, Tenn. and GLEN ROCK, N.J., ... 76 percent of surveyed pharmacy directors say that by ... only one preferred biologic for all immune conditions, such ... According to the new Formulary Forum report entitled ...
... , , , ... GHDX ) today announced that Kim Popovits, Genomic Health,s Chief ... Growth Conference in Boston, on Thursday, August 13 at 1:30 p.m. ... subsequently archived webcast of the presentation, visit the Investor Relations section ...
... , , HOUSTON, Aug. 6 ... a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated ... trial is being conducted under a Bellicum Investigational New Drug application ... results of the study in 2010. , , ...
... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
... , , NEW YORK, ... synthetic peptide technology shown to significantly help improve the appearance of ... now available through select physicians to help their patients achieve picture ... can be found in leading physician offices for $120 per 1 ...
... , SALT LAKE CITY, Aug. 6 ... silicon nitride ceramic technologies, announced today that Ben Shappley has joined ... Shappley will also serve on the company,s Board of Directors. , ... of orthopaedic and neurosurgical implant experience in both management and senior ...
Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:Ben Shappley Joins Amedica's Leadership Team 2
... a differential medium designed for the ... Selective agents are incorporated for the ... of S. epidermidis and yeast. S. ... in mauve colonies, thus permitting differentiation ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... a 180 watt Xenon short arc lamp. Designed to ... the lamp to the light guide, this light source ... higher watt bulbs. A new IR filtering system and ... amount of heat generated from the light source and ...
... standardize your video equipment has led Linvatec ... couplers to accommodate all of your multi-specialty ... "V mount couplers in both traditional eyecup ... also offer a 20-42mm Zoom "C mount ...
Medicine Products: